William Blair analyst Sami Corwin has reiterated their bullish stance on NGNE stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sami Corwin has given his Buy rating due to a combination of factors that position Neurogene favorably in the market. The company has recently dosed the first patient in its pivotal Embolden trial for NGN-401, a gene therapy aimed at treating Rett syndrome, which places it ahead of competitors in terms of market readiness. With 12 out of 13 trial sites already activated, Neurogene is progressing swiftly and expects to complete enrollment within three to six months, potentially making it the first to market.
Neurogene’s strategic alignment with the FDA, particularly through the START designation, minimizes regulatory risks that have affected other companies in the neuro field. This designation has facilitated continuous communication with the FDA, even amidst leadership changes, ensuring that the trial’s design and statistical analysis plan meet regulatory expectations. These factors, combined with the potential for a timely submission of NGN-401 for approval by mid- to late 2027, underpin Corwin’s optimistic Buy rating for Neurogene’s stock.
According to TipRanks, Corwin is a 5-star analyst with an average return of 25.7% and a 54.82% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Solid Biosciences, Cabaletta Bio, and PTC Therapeutics.